• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

胰高血糖素样肽-1受体激动剂治疗患者胃肠道症状管理的饮食建议

Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist.

作者信息

Gentinetta Silvia, Sottotetti Francesca, Manuelli Matteo, Cena Hellas

机构信息

Novo Nordisk Italia SpA, Roma, Italy.

Laboratory of Dietetics and Clinical Nutrition, Department of Public Health, Experimental and Forensic Medicine, University of Pavia, Pavia, Italy.

出版信息

Diabetes Metab Syndr Obes. 2024 Dec 19;17:4817-4824. doi: 10.2147/DMSO.S494919. eCollection 2024.

DOI:10.2147/DMSO.S494919
PMID:39722834
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11668918/
Abstract

GLP-1 receptor agonist (GLP-1RA) have been developed to address the global burden of obesity and are renowned for their safety and efficacy. These medications influence hunger and satiety, reducing energy intake and promoting weight loss. Despite their benefits, GLP-1RAmay cause a slowed gastric emptying, leading to gastrointestinal symptoms. This study examines how food properties and meal composition affect these symptoms. Dietary recommendations are provided, particularly for evening meals, focusing on how different foods and nutrients can influence the rate of gastric emptying, to improve patient compliance and prevent interruption in weight loss.

摘要

胰高血糖素样肽-1受体激动剂（GLP-1RA）已被研发用于应对全球肥胖负担，并且以其安全性和有效性而闻名。这些药物会影响饥饿感和饱腹感，减少能量摄入并促进体重减轻。尽管它们有诸多益处，但GLP-1RA可能会导致胃排空减慢，从而引发胃肠道症状。本研究探讨食物特性和膳食组成如何影响这些症状。文中提供了饮食建议，特别是针对晚餐的建议，重点关注不同食物和营养素如何影响胃排空速率，以提高患者的依从性并防止体重减轻过程受到干扰。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec06/11668918/6601e80f04eb/DMSO-17-4817-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec06/11668918/6601e80f04eb/DMSO-17-4817-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ec06/11668918/6601e80f04eb/DMSO-17-4817-g0001.jpg

相似文献

1
Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist.胰高血糖素样肽-1受体激动剂治疗患者胃肠道症状管理的饮食建议
Diabetes Metab Syndr Obes. 2024 Dec 19;17:4817-4824. doi: 10.2147/DMSO.S494919. eCollection 2024.
2
Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men.胰高血糖素样肽1可延长肥胖男性餐后饱腹感的持续时间并减缓胃排空。
Am J Clin Nutr. 1998 Sep;68(3):525-30. doi: 10.1093/ajcn/68.3.525.
3
Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies.关于新型基于胰高血糖素样肽-1受体激动剂（GLP-1RA）的减肥疗法的使用、临床及对比疗效和不良反应的真实世界证据。
Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8.
4
The effects of fiber enrichment of pasta and fat content on gastric emptying, GLP-1, glucose, and insulin responses to a meal.面食的纤维强化和脂肪含量对胃排空、胰高血糖素样肽-1、血糖及胰岛素对一餐的反应的影响。
Eur J Clin Nutr. 2003 Feb;57(2):293-8. doi: 10.1038/sj.ejcn.1601520.
5
The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials.GLP-1类似物对肥胖成年人食欲参数、胃排空、食物偏好和味觉的疗效：随机对照试验的系统评价
Diabetes Metab Syndr Obes. 2023 Mar 2;16:575-595. doi: 10.2147/DMSO.S387116. eCollection 2023.
6
The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity.胰高血糖素样肽-1生理水平对肥胖者食欲、胃排空、能量及底物代谢的影响。
Int J Obes Relat Metab Disord. 2001 Jun;25(6):781-92. doi: 10.1038/sj.ijo.0801627.
7
Gastric electrical stimulation: an evidence-based analysis.胃电刺激：基于证据的分析。
Ont Health Technol Assess Ser. 2006;6(16):1-79. Epub 2006 Aug 1.
8
Weight Loss and Maintenance Related to the Mechanism of Action of Glucagon-Like Peptide 1 Receptor Agonists.GLP-1 受体激动剂作用机制与体重减轻和维持的关系。
Adv Ther. 2021 Jun;38(6):2821-2839. doi: 10.1007/s12325-021-01710-0. Epub 2021 May 11.
9
A Pilot Study Examining the Effects of GLP-1 Receptor Blockade Using Exendin-(9,39) on Gastric Emptying and Caloric Intake in Subjects With and Without Bariatric Surgery.一项探讨 GLP-1 受体阻断剂 Exendin-(9,39) 对接受和未接受减重手术患者胃排空和热量摄入影响的初步研究。
Metab Syndr Relat Disord. 2020 Nov;18(9):406-412. doi: 10.1089/met.2020.0049. Epub 2020 Aug 20.
10
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide.胰高血糖素样肽-1受体激动剂和替尔泊肽导致胃排空延迟的临床后果
J Clin Endocrinol Metab. 2024 Dec 18;110(1):1-15. doi: 10.1210/clinem/dgae719.

引用本文的文献

1
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment.高效抗肥胖治疗时代的肥胖生活方式医学
Nutrients. 2025 Jul 21;17(14):2382. doi: 10.3390/nu17142382.
2
Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.支持胰高血糖素样肽-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会的联合咨询意见
Obes Pillars. 2025 Jun 3;15:100181. doi: 10.1016/j.obpill.2025.100181. eCollection 2025 Sep.
3

本文引用的文献

1
Understanding the mechanism of high viscosity food delaying gastric emptying.了解高黏度食物延缓胃排空的机制。
Food Funct. 2024 May 20;15(10):5382-5396. doi: 10.1039/d4fo00319e.
2
Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease.下丘脑通过摄食控制体脂量：理解肥胖应被视为一种疾病的关键。
Diabetes Obes Metab. 2024 Apr;26 Suppl 2:3-12. doi: 10.1111/dom.15478. Epub 2024 Feb 14.
3
Dietary impact on fasting and stimulated GLP-1 secretion in different metabolic conditions - a narrative review.
Nutritional Priorities to Support GLP-1 Therapy for Obesity: A Joint Advisory From the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society.
支持胰高血糖素样肽-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会联合咨询意见
Am J Lifestyle Med. 2025 May 30:15598276251344827. doi: 10.1177/15598276251344827.
4
Nutritional priorities to support GLP-1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society.支持GLP-1治疗肥胖症的营养优先事项：美国生活方式医学学院、美国营养学会、肥胖医学协会和肥胖协会联合发布的咨询意见
Obesity (Silver Spring). 2025 May 30. doi: 10.1002/oby.24336.
不同代谢状况下饮食对空腹及刺激后胰高血糖素样肽-1分泌的影响——一篇叙述性综述
Am J Clin Nutr. 2024 Mar;119(3):599-627. doi: 10.1016/j.ajcnut.2024.01.007. Epub 2024 Jan 11.
4
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.胰高血糖素样肽-1受体激动剂用于减肥时胃肠道不良事件的风险
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574.
5
The role of food structure in gastric-emptying rate, absorption and metabolism.食物结构在胃排空率、吸收和代谢中的作用。
Proc Nutr Soc. 2024 Feb;83(1):35-41. doi: 10.1017/S0029665123003609. Epub 2023 Sep 6.
6
Macronutrients effects on satiety and food intake in older and younger adults: A randomised controlled trial.宏量营养素对老年人和年轻人饱腹感和食物摄入的影响：一项随机对照试验。
Appetite. 2023 Oct 1;189:106982. doi: 10.1016/j.appet.2023.106982. Epub 2023 Jul 26.
7
Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials.GLP-1 激动剂在肥胖中的新作用：随机对照试验的综合综述。
Int J Mol Sci. 2023 Jun 21;24(13):10449. doi: 10.3390/ijms241310449.
8
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus.管理接受胰高血糖素样肽-1受体激动剂治疗患者胃肠道不良事件的临床建议：多学科专家共识
J Clin Med. 2022 Dec 24;12(1):145. doi: 10.3390/jcm12010145.
9
Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.不同 GLP-1 受体激动剂与胃肠道不良反应的关联性：基于 FDA 不良事件报告系统数据库的真实世界药物不良反应比例性研究。
Front Endocrinol (Lausanne). 2022 Dec 7;13:1043789. doi: 10.3389/fendo.2022.1043789. eCollection 2022.
10
Modern vision of the Mediterranean diet.地中海饮食的现代观。
J Prev Med Hyg. 2022 Oct 17;63(2 Suppl 3):E36-E43. doi: 10.15167/2421-4248/jpmh2022.63.2S3.2745. eCollection 2022 Jun.